Business Context and Reporting Period
Company: OraSure Technologies, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 29, 2003
Event: The Company announced the filing of an application with the U.S. Food and Drug Administration (FDA) for pre-market approval of its OraQuick® Rapid HIV-1 Antibody Test. This test is designed to detect HIV-1 antibodies in oral fluid and plasma samples.
Financial Metrics
This filing is a Current Report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material change reported is the strategic milestone of submitting a pre-market approval application to the FDA for the OraQuick® Rapid HIV-1 Antibody Test. No financial performance changes versus prior periods are disclosed in this document.
Guidance, Outlook, and Risks
Management Commentary: The filing incorporates by reference a press release dated September 29, 2003, detailing the FDA application. The document does not provide specific financial guidance, future outlook projections, or a detailed discussion of risks and contingencies beyond the regulatory submission itself.
Key Facts for Investor Verification
- Verify the status of the FDA pre-market approval application for the OraQuick® Rapid HIV-1 Antibody Test.
- Review the full text of the press release attached as Exhibit 99 for additional details on the test's capabilities and market potential.
- Monitor subsequent filings for the FDA's decision on the pre-market approval application.